60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reiterated by investment analysts at Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

A number of other research analysts have also recently commented on SXTP. HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 28th. Wall Street Zen cut 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Finally, Ascendiant Capital Markets boosted their price target on 60 Degrees Pharmaceuticals from $5.80 to $7.00 and gave the stock a “buy” rating in a report on Monday, June 2nd.

60 Degrees Pharmaceuticals Stock Down 5.7%

SXTP stock opened at $2.30 on Friday. 60 Degrees Pharmaceuticals has a twelve month low of $1.41 and a twelve month high of $35.99. The stock has a market cap of $3.38 million, a P/E ratio of -0.05 and a beta of 2.88. The business’s 50-day moving average price is $2.47 and its 200-day moving average price is $3.28.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.25). The firm had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.15 million. On average, equities research analysts expect that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.